Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) Short Interest Down 70.1% in June

Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) was the recipient of a significant decline in short interest during the month of June. As of June 30th, there was short interest totaling 6,105 shares, a decline of 70.1% from the June 15th total of 20,390 shares. Based on an average daily volume of 64,461 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.1% of the shares of the stock are sold short.

Matinas Biopharma Stock Up 20.5%

Matinas Biopharma stock traded up $0.13 during midday trading on Friday, reaching $0.76. 1,681,787 shares of the stock traded hands, compared to its average volume of 126,202. The stock’s fifty day moving average is $0.68 and its 200-day moving average is $0.63. Matinas Biopharma has a 12 month low of $0.48 and a 12 month high of $3.09. The stock has a market cap of $4.84 million, a P/E ratio of -0.38 and a beta of 1.71.

Matinas Biopharma (NYSEAMERICAN:MTNB) last released its quarterly earnings results on Friday, May 8th. The company reported ($0.30) earnings per share for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Matinas Biopharma stock. DRW Securities LLC acquired a new stake in shares of Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 46,374 shares of the company’s stock, valued at approximately $27,000. DRW Securities LLC owned about 0.72% of Matinas Biopharma as of its most recent SEC filing. 11.77% of the stock is currently owned by institutional investors and hedge funds.

Matinas Biopharma Company Profile

Matinas Biopharma Inc is a clinical‐stage biopharmaceutical company that specializes in the development of novel lipid‐based drug delivery platforms. Its proprietary Lipid NanoSphere (LNS) technology is designed to encapsulate water‐soluble and hydrophobic therapeutic agents, enabling both oral and intravenous administration. The company’s approach aims to improve drug pharmacokinetics, enhance bioavailability and reduce systemic toxicity compared with conventional formulations.

The lead product candidate, MAT2203, is an oral formulation of amphotericin B being developed for the treatment of cryptococcal meningitis and other life‐threatening fungal infections.